The present invention relates to compounds of formula I
wherein R
1
and R
2
are as defined in the specification and to pharmaceutically acceptable salts thereof for the treatment of diseases, which are mediated by monoamine oxidase B inhibitors, for example Alzheimer's disease and senile dementia.